Can I Take NAC (N-Acetylcysteine) with Egrifta (Tesamorelin)?
HealthRX.com
No listed interaction between NAC and Egrifta, but no human data
At a glance
- Interaction listed between tesamorelin and NAC / None in either label [1][2]
- Egrifta SV dose / 1.4 mg subcutaneously once daily [1]
- Egrifta WR dose / 1.28 mg subcutaneously once daily [3]
- What the Egrifta label asks to be monitored / IGF-1 and glucose [1]
- NAC's documented drug interaction / With nitroglycerin: can intensify nitroglycerin-related headache and cranial artery dilation [4][5]
- NAC regulatory status / Prescription drug since 1963; supplement sales under FDA enforcement discretion [6][7]
- NAC side effects at trial doses in chronic respiratory disease / Stomach and gut symptoms, no more common than in control groups [8]
What the Egrifta SV label lists as interactions
Egrifta SV's Drug Interactions section has two entries, and NAC appears in neither [1].
The first covers drugs metabolized by cytochrome P450 enzymes. Growth hormone may alter CYP450-mediated clearance, and the label names corticosteroids, sex steroids, anticonvulsants and cyclosporine as examples, asking prescribers to monitor when tesamorelin is given with them [1]. In healthy subjects, tesamorelin changed simvastatin exposure by about -8% (simvastatin acid -15%) and ritonavir exposure by about -9%, which the label describes as no significant impact [1].
The second entry covers glucocorticoids. GH inhibits 11β-hydroxysteroid dehydrogenase type 1, the enzyme that converts cortisone to cortisol, and the label says people receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin, with cortisone acetate and prednisone affected more than other steroids [1].
What the acetylcysteine label says
The prescription acetylcysteine label's drug interaction section is a single sentence: the stability and safety of mixing acetylcysteine with other drugs in a nebulizer have not been established [2]. That label covers the 10% and 20% solutions, used by inhalation as a mucus thinner and by mouth as an antidote to prevent or lessen liver injury after a potentially hepatotoxic acetaminophen overdose, with treatment started within 24 hours [2].
Capsules, tablets and powders sold as NAC supplements are not covered by that label. FDA's position is that NAC is excluded from the legal definition of a dietary supplement because it was approved as a drug on September 14, 1963, and FDA is not aware of any marketing of NAC as a supplement or food before that date [6][9]. Since its August 2022 final guidance, FDA has said it intends not to object to compliant NAC products labeled as dietary supplements while it considers rulemaking, which is enforcement discretion rather than approval [6][7].
NAC's documented interaction with nitroglycerin
In 11 healthy volunteers, NAC 100 mg/kg given before a nitroglycerin infusion made the headache worse (median score 3 vs 1 with placebo) and increased temporal artery dilation to 139% of baseline vs 127% [4].
In a randomized double-blind trial of 200 patients with unstable angina followed for 4 months, side effects, mainly intolerable headache, occurred in 35% of the group on transdermal nitroglycerin plus oral NAC, almost twice as often as with nitroglycerin alone. That group also had fewer deaths, heart attacks or refractory angina events (13%, vs 31% on nitroglycerin, 42% on NAC and 39% on placebo) [5][11]. Neither study involved tesamorelin.
What the Egrifta label asks prescribers to watch
IGF-1: among people treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those who stayed on treatment to 52 weeks, 34% and 23% [1]. The label asks prescribers to monitor IGF-1 during therapy and to consider discontinuing tesamorelin for persistent elevations, for example above 3 SDS, particularly when the fat-loss response is not robust [1].
Glucose: an HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6), and the label asks that glucose status be evaluated before treatment and monitored during it [1].
NAC in people with HIV
A 1997 study in the Proceedings of the National Academy of Sciences found that glutathione deficiency in CD4 T cells from HIV-infected people was associated with markedly lower survival two to three years later, and that oral NAC replenished glutathione in those subjects [10]. The authors suggested that NAC administration could improve survival [10].
NAC doses and side effects
A review of 41 studies in chronic respiratory disease notes a maximum licensed chronic dose of 600 mg per day in respiratory medicine; the studies used 600 mg up to 3,000 mg per day, mostly by mouth, and stomach and gut symptoms were reported but were no more common than in the control groups [8].
The acetylcysteine label lists stomatitis, nausea, vomiting, fever, rhinorrhea, drowsiness, clamminess, chest tightness and bronchoconstriction among adverse effects, and notes that oral use in the large doses needed for acetaminophen overdose may cause nausea, vomiting and other gastrointestinal symptoms; rash with or without mild fever is rare [2].
What is unknown
Whether NAC shifts tesamorelin's IGF-1, glucose or visceral fat response has not been measured in people. The Egrifta SV label warns about elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity reactions and injection-site reactions. In its trials, hypersensitivity reactions occurred in 4% of patients, and injection-site reactions occurred in 25% of tesamorelin-treated patients versus 14% of placebo-treated patients [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Does NAC interact with Egrifta (tesamorelin)?
What side effects does each product carry on its own?
Which NAC products does the prescription label cover?
What does the Egrifta label monitor?
Is NAC approved for HIV?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What is N-Acetylcysteine (NAC) used for?
The prescription acetylcysteine label covers 10% and 20% solutions. Inhaled, NAC works as a mucus thinner. Taken by mouth, it is an antidote that prevents or lessens liver injury after a potentially hepatotoxic acetaminophen overdose, with treatment started within 24 hours. Capsules and powders sold as NAC supplements are not covered by that label.
How long does it take for NAC to convert to glutathione?
No time frame is established. A 1997 study in people with HIV found that oral NAC replenished glutathione in their CD4 T cells, but it does not report how long that took.
References
Show all 11 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Acetylcysteine oral and inhalation solution prescribing information. Acetylcysteine oral and inhalation solution label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Iversen HK. N-acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses. Clin Pharmacol Ther. 1992;52(2):125-33.
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol. 1997;29(5):941-7.
- U.S. Food and Drug Administration.
- FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products | FDA.
- Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021;44(3):273-290.
- U.S. Food and Drug Administration.
- Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997;94(5):1967-72.
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol. 1997. Outcome events in the unstable angina trial